Evidence map›Paper›PMID 40610228›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [

Raghava Kashyap, James P Buteau, Mathias Bressel, Michal Eifer, Neeraja Bollampally, Price Jackson, Lachlan McIntosh, Shahneen Sandhu, Michael S Hofman

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The predictive role of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. The Prognostic Value ofAnnals of nuclear medicine · 2026
    Article
  4. Prognostic Value of Cycle 1 SPECT SUVJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  5. Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raghava KashyapProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; kashyap.karri@petermac.org michael.hofman@petermac.org.
James P ButeauProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Mathias BresselSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Michal EiferProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Neeraja BollampallyProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Price JacksonProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Lachlan McIntoshProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Shahneen SandhuProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Michael S HofmanProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; kashyap.karri@petermac.org michael.hofman@petermac.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data are emerging on the prognostic significance of quantitative changes on posttherapy SPECT/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving [

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsSingle Photon Emission Computed Tomography Computed TomographyAgedAged, 80 and overHumansMaleMiddle AgedPrognosisProstate-Specific AntigenRadioisotopesSurvival AnalysisTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177PluvictoProstate-Specific AntigenPSMA-617RadioisotopesRadiopharmaceuticalsimaging biomarkerLu-PSMAmCRPCposttherapy SPECTprostate cancerradionuclide therapy

Identifiers

PMID40610228
PMCPMC13670944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.